The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.
As patients become older, additional factors must be considered in planning their treatment.
Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.
Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.
Not conducting a second tissue biopsy could have dangerous implications for the patient according to a recent article.
An emerging approach in the early stages of clinical development for MM is oncolytic virotherapy, in which viruses are used to eliminate cancer cells directly or indirectly.
As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.
Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.
There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which is associated with specific germline mutations, including von Hippel-Lindau disease (VHL).
Clinicians can use a geriatric assessment for an objective appraisal of the health status of older patients with multiple myeloma.
Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?
Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.
Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively safe side effect profile.
SABR may be used to improve PFS, or potentially OS, among patients who have a good response to chemotherapy, targeted therapy, or immunotherapy.
The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- beta-Carotene and Cancer
- Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified
- Venetoclax Plus Rituximab May Prolong Progression-free Survival in CLL
- Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer
- Different Types of Obesity May Increase Risk of Breast Cancer Subtypes